Merck (NYSE:MRK) is approaching phase 2 data for Winrevair in pulmonary hypertension. Results will focus on the 6 minute walk ...
A subcutaneously injected version of Merck cancer immunotherapy Keytruda is now FDA approved, a regulatory decision that gives patients a less burdensome dosing option and provides the pharmaceutical ...
Merck and Mayo Clinic have launched a strategic collaboration to integrate multimodal clinical data with AI to accelerate drug discovery and target identification. 2. The partnership leverages secure, ...
In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions similar to those observed with existing injectables. The results from two phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results